Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 710 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016, provides an overview of the Diffuse Large B-Cell Lymphoma (Oncology) pipeline landscape.

Diffuse large B-cell lymphoma, a type of non-Hodgkin lymphoma, is a cancer of B-cells. The lymphoma may metastasize to other organs such as the liver, lungs or the bones. The signs and symptoms of diffuse large B-cell lymphoma may include painless swelling in the neck, armpit or groin caused by enlarged lymph nodes, loss of appetite, tiredness, night sweats, unexplained high temperatures, and weight loss. The possible treatments for diffuse large B-cell lymphoma include radiation, chemotherapy, steroid therapy in combination with chemotherapy, high-dose chemotherapy with stem cell support and monoclonal antibody therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diffuse Large B-Cell Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diffuse Large B-Cell Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Diffuse Large B-Cell Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 57, 38, 30 and 5 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 2, 1 and 1 molecules, respectively for Diffuse Large B-Cell Lymphoma.

Diffuse Large B-Cell Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Diffuse Large B-Cell Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diffuse Large B-Cell Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diffuse Large B-Cell Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diffuse Large B-Cell Lymphoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diffuse Large B-Cell Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 7
Diffuse Large B-Cell Lymphoma Overview 8
Therapeutics Development 9
Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies 11
Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 17
Diffuse Large B-Cell Lymphoma - Pipeline Products Glance 18
Diffuse Large B-Cell Lymphoma - Products under Development by Companies 21
Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes 31
Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development 32
Diffuse Large B-Cell Lymphoma - Therapeutics Assessment 110
Drug Profiles 126
Diffuse Large B-Cell Lymphoma - Dormant Projects 678
Diffuse Large B-Cell Lymphoma - Discontinued Products 682
Diffuse Large B-Cell Lymphoma - Product Development Milestones 684
Appendix 695

List of Tables

Number of Products under Development for Diffuse Large B-Cell Lymphoma, H2 2016 25
Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H2 2016 26
Number of Products under Development by Companies, H2 2016 27
Number of Products under Development by Companies, H2 2016 (Contd..1) 28
Number of Products under Development by Companies, H2 2016 (Contd..2) 29
Number of Products under Development by Companies, H2 2016 (Contd..3) 30
Number of Products under Development by Companies, H2 2016 (Contd..4) 31
Number of Products under Development by Companies, H2 2016 (Contd..5) 32
Number of Products under Investigation by Universities/Institutes, H2 2016 33
Comparative Analysis by Late Stage Development, H2 2016 34
Comparative Analysis by Clinical Stage Development, H2 2016 35
Comparative Analysis by Early Stage Development, H2 2016 36
Products under Development by Companies, H2 2016 37
Products under Development by Companies, H2 2016 (Contd..1) 38
Products under Development by Companies, H2 2016 (Contd..2) 39
Products under Development by Companies, H2 2016 (Contd..3) 40
Products under Development by Companies, H2 2016 (Contd..4) 41
Products under Development by Companies, H2 2016 (Contd..5) 42
Products under Development by Companies, H2 2016 (Contd..6) 43
Products under Development by Companies, H2 2016 (Contd..7) 44
Products under Development by Companies, H2 2016 (Contd..8) 45
Products under Development by Companies, H2 2016 (Contd..9) 46
Products under Investigation by Universities/Institutes, H2 2016 47
Diffuse Large B-Cell Lymphoma - Pipeline by 3SBio Inc., H2 2016 48
Diffuse Large B-Cell Lymphoma - Pipeline by AbbVie Inc, H2 2016 49
Diffuse Large B-Cell Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 50
Diffuse Large B-Cell Lymphoma - Pipeline by Affimed GmbH , H2 2016 51
Diffuse Large B-Cell Lymphoma - Pipeline by Amgen Inc., H2 2016 52
Diffuse Large B-Cell Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H2 2016 53
Diffuse Large B-Cell Lymphoma - Pipeline by Arvinas, Inc., H2 2016 54
Diffuse Large B-Cell Lymphoma - Pipeline by Asana BioSciences, LLC, H2 2016 55
Diffuse Large B-Cell Lymphoma - Pipeline by AstraZeneca Plc, H2 2016 56
Diffuse Large B-Cell Lymphoma - Pipeline by Aurigene Discovery Technologies Limited, H2 2016 57
Diffuse Large B-Cell Lymphoma - Pipeline by Bayer AG, H2 2016 58
Diffuse Large B-Cell Lymphoma - Pipeline by BeiGene, Ltd., H2 2016 59
Diffuse Large B-Cell Lymphoma - Pipeline by Biocon Limited, H2 2016 60
Diffuse Large B-Cell Lymphoma - Pipeline by BioNTech AG, H2 2016 61
Diffuse Large B-Cell Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 62
Diffuse Large B-Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 63
Diffuse Large B-Cell Lymphoma - Pipeline by Celgene Corporation, H2 2016 64
Diffuse Large B-Cell Lymphoma - Pipeline by Cell Medica Limited, H2 2016 65
Diffuse Large B-Cell Lymphoma - Pipeline by Cell>Point, L.L.C., H2 2016 66
Diffuse Large B-Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2016 67
Diffuse Large B-Cell Lymphoma - Pipeline by Clevexel Pharma SA, H2 2016 68
Diffuse Large B-Cell Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2016 69
Diffuse Large B-Cell Lymphoma - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 70
Diffuse Large B-Cell Lymphoma - Pipeline by CTI BioPharma Corp., H2 2016 71
Diffuse Large B-Cell Lymphoma - Pipeline by Curis, Inc., H2 2016 72
Diffuse Large B-Cell Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016 73
Diffuse Large B-Cell Lymphoma - Pipeline by eFFECTOR Therapeutics, Inc., H2 2016 74
Diffuse Large B-Cell Lymphoma - Pipeline by Eisai Co., Ltd., H2 2016 75
Diffuse Large B-Cell Lymphoma - Pipeline by EpiZyme, Inc., H2 2016 76
Diffuse Large B-Cell Lymphoma - Pipeline by Erytech Pharma SA, H2 2016 77
Diffuse Large B-Cell Lymphoma - Pipeline by Evotec AG, H2 2016 78
Diffuse Large B-Cell Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 79
Diffuse Large B-Cell Lymphoma - Pipeline by Genentech, Inc., H2 2016 80
Diffuse Large B-Cell Lymphoma - Pipeline by Genosco, H2 2016 81
Diffuse Large B-Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2016 82
Diffuse Large B-Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2016 83
Diffuse Large B-Cell Lymphoma - Pipeline by H3 Biomedicine Inc., H2 2016 84
Diffuse Large B-Cell Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2016 85
Diffuse Large B-Cell Lymphoma - Pipeline by ImmunoGen, Inc., H2 2016 86
Diffuse Large B-Cell Lymphoma - Pipeline by Immunomedics, Inc., H2 2016 87
Diffuse Large B-Cell Lymphoma - Pipeline by Immunovaccine, Inc., H2 2016 88
Diffuse Large B-Cell Lymphoma - Pipeline by Incyte Corporation, H2 2016 89
Diffuse Large B-Cell Lymphoma - Pipeline by Inflection Biosciences Limited, H2 2016 90
Diffuse Large B-Cell Lymphoma - Pipeline by Innovent Biologics, Inc., H2 2016 91
Diffuse Large B-Cell Lymphoma - Pipeline by Johnson & Johnson, H2 2016 92
Diffuse Large B-Cell Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2016 93
Diffuse Large B-Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 94
Diffuse Large B-Cell Lymphoma - Pipeline by Kite Pharma Inc, H2 2016 95
Diffuse Large B-Cell Lymphoma - Pipeline by Mabion SA, H2 2016 96
Diffuse Large B-Cell Lymphoma - Pipeline by mAbxience S.A., H2 2016 97
Diffuse Large B-Cell Lymphoma - Pipeline by MedImmune LLC, H2 2016 98
Diffuse Large B-Cell Lymphoma - Pipeline by Medivation, Inc., H2 2016 99
Diffuse Large B-Cell Lymphoma - Pipeline by Merck & Co., Inc., H2 2016 100
Diffuse Large B-Cell Lymphoma - Pipeline by Merck KGaA, H2 2016 101
Diffuse Large B-Cell Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 102
Diffuse Large B-Cell Lymphoma - Pipeline by Mirati Therapeutics Inc., H2 2016 103
Diffuse Large B-Cell Lymphoma - Pipeline by Molplex Ltd., H2 2016 104
Diffuse Large B-Cell Lymphoma - Pipeline by MorphoSys AG, H2 2016 105
Diffuse Large B-Cell Lymphoma - Pipeline by Neumedicines Inc., H2 2016 106
Diffuse Large B-Cell Lymphoma - Pipeline by Nimbus Therapeutics, LLC, H2 2016 107
Diffuse Large B-Cell Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2016 108
Diffuse Large B-Cell Lymphoma - Pipeline by Novartis AG, H2 2016 109
Diffuse Large B-Cell Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 110
Diffuse Large B-Cell Lymphoma - Pipeline by Pfizer Inc., H2 2016 111
Diffuse Large B-Cell Lymphoma - Pipeline by Philogen S.p.A., H2 2016 112
Diffuse Large B-Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2016 113
Diffuse Large B-Cell Lymphoma - Pipeline by RedHill Biopharma Ltd., H2 2016 114
Diffuse Large B-Cell Lymphoma - Pipeline by Respiratorius AB, H2 2016 115
Diffuse Large B-Cell Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 116
Diffuse Large B-Cell Lymphoma - Pipeline by Sandoz International GmbH, H2 2016 117
Diffuse Large B-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2016 118
Diffuse Large B-Cell Lymphoma - Pipeline by Selvita S.A., H2 2016 119
Diffuse Large B-Cell Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016 120
Diffuse Large B-Cell Lymphoma - Pipeline by Sigma-Tau S.p.A., H2 2016 121
Diffuse Large B-Cell Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 122
Diffuse Large B-Cell Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 123
Diffuse Large B-Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2016 124
Diffuse Large B-Cell Lymphoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 125
Assessment by Monotherapy Products, H2 2016 126
Assessment by Combination Products, H2 2016 127
Number of Products by Stage and Target, H2 2016 129
Number of Products by Stage and Mechanism of Action, H2 2016 134
Number of Products by Stage and Route of Administration, H2 2016 139
Number of Products by Stage and Molecule Type, H2 2016 141
Diffuse Large B-Cell Lymphoma - Dormant Projects, H2 2016 692
Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..1), H2 2016 693
Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..2), H2 2016 694
Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..3), H2 2016 695
Diffuse Large B-Cell Lymphoma - Discontinued Products, H2 2016 696
Diffuse Large B-Cell Lymphoma - Discontinued Products (Contd..1), H2 2016 697